Navigation Links
OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study
Date:10/29/2010

PORTLAND, Ore. Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

The Phase Ib trial, sponsored by StemCells, Inc., is designed to further assess the safety and preliminary effectiveness of StemCells' HuCNS-SC as a potential treatment for NCL, also referred to as Batten disease. This second trial is expected to enroll six children whose NCL is less advanced than those enrolled in the initial Phase I trial, also carried out at OHSU Doernbecher, and, in addition to safety, is also designed to evaluate the impact of HuCNS-SC on disease progression.

"The hard work of testing neural stem cells for their safety and effectiveness in clinical use began here at OHSU Doernbecher Children's Hospital. We are very pleased to carry on this important effort with a second major trial. Our great hope is that this work will eventually yield significant benefits for patients who suffer from devastating nervous system diseases," said Nathan Selden, M.D., Ph.D., FACS, FAAP, Campagna Professor of Pediatric Neurosurgery and head of the Division of Pediatric Neurological Surgery at OHSU Doernbecher Children's Hospital, OHSU School of Medicine.

Selden was co-principal investigator on the groundbreaking initial Phase I trial and will lead the Ib study.

The initial trial was the first-ever FDA-authorized clinical trial of purified human neural stem cells as a potential therapeutic agent. Begun in March 2006, its aim was to test the safety and preliminary efficacy of transplanting HuCNS-SC in six children with advanced stages of NCL. Once transplanted, the children were followed for 12 months. Data from the Phase I trial, completed in January 2009, demonstrated that high doses of HuCNS-SC transplanted directly into multiple sites within the brain followed by 12 months of immunosuppression were well tolerated. The data also included evidence of engraftment and long-term survival of the donor cells.

Participants in the new study will be transplanted with HuCNS-SC via a neurosurgical procedure and their immune systems will be suppressed for nine months. Following transplantation, the children will be monitored and regularly evaluated for 12 months to assess the safety and tolerability of the HuCNS-SC, the surgery and the immunosuppression. In addition, participants will be evaluated and assessed at regular intervals using a comprehensive range of clinical and X-ray tests, both before transplantation to establish a baseline, and over the course of 12 months following transplantation.

StemCells, Inc. will initiate a separate four-year observational study at the conclusion of this trial.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related biology news :

1. Childrens Hospital LA discovers growth factor essential to epicardial cell function
2. Malnutrition increases risk of prolonged hospital stay
3. McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research
4. Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers
5. Opioid use to relieve pain and suffering at end of life is safe in hospital-at-home setting
6. Researchers at Childrens Hospital Los Angeles find diet-induced obesity accelerates leukemia
7. Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security
8. Texas Childrens Hospital vaccine experts present 4 studies
9. Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms
10. Temple University Hospital and PASNAP Negotiations Break Off: Talks to Resume Later Today
11. Researchers find Clostridium difficile is more common than MRSA in southeast community hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a ... of innovative biopharmaceutical products for companion animals, will host a ... a.m. ET to discuss financial results from the fourth quarter ... Interested participants and investors may access the audio webcast ... ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced ... presenting at the Annual Biocom Global Life Science Partnering ... at 11:15 AM, at the Torrey Pines Lodge, in ... the organizers at Biocom who have chosen our company, ... of biotechnology companies, investors, and clinical researchers," said Mr. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... development of precision treatments for neurodegenerative diseases, today announced it has issued a ... approach.” This is one of a series of commentaries from ProMIS’s scientific team ...
(Date:2/22/2017)... Dublin - Research and Markets has ... Market-By Type, By Application, By End User, By Region, By Country: ... ... Market is forecasted to grow at a CAGR of 11.33% during ... crop protection market is driven by the surging demand for less ...
Breaking Biology Technology: